London, UK, 23-10-2013 — /EuropaWire/ — GlaxoSmithKline plc (LSE:GSK) today announced the submission of a New Drug Application (NDA) in the US for the once daily inhaled corticosteroid (ICS) treatment, fluticasone furoate (FF), administered using the ELLIPTA™ dry powder inhaler. The NDA … Read the full press release
Posted in Government, Healthcare, Pharma & Biotech, Science, United Kingdom
Tagged asthma, Bradd Pavur, Catherine Hartley, David Daley, David Mawdsley, ELLIPTA™, ELLIPTA™ dry powder inhaler, fluticasone furoate (FF), fluticasone furoate monotherapy, Gary Davies, GlaxoSmithKline, GlaxoSmithKline plc, GSK, James Dodwell, Jeff McLaughlin, Juan Carlos Molina, Karen Collins, Kirsty Collins (SRI & CG), LSE:GSK, Lucy Singah, Melinda Stubbee, NDA, New Drug Application (NDA), once daily inhaled corticosteroid (ICS) treatment, Simon Steel, Stephen Rea, Tom Curry, US FDA, US regulatory submission, Ziba Shamsi
London, UK, 23-10-2013 — /EuropaWire/ — ViiV Healthcare today announced the submission of a regulatory application in the United States for its investigational single-tablet regimen (STR) combining dolutegravir, abacavir and lamivudine for the treatment of people living with HIV-1. This New Drug … Read the full press release
Posted in Government, Healthcare, Pharma & Biotech, Science, United Kingdom
Tagged abacavir, antiretroviral agents, David Daley, dolutegravir, Gary Davies, GlaxoSmithKline, GSK, HIV, HIV-1, James Dodwell, Jeff McLaughlin, lamivudine, Lucy Budd, Marc Meachem, Marketing Authorisation Application, Melinda Stubbee, New Drug Application (NDA), people living with HIV, Pfizer, Rebecca Hunt, single-tablet regimen, Tivicay®, Tom Curry, treatment of HIV-1, US Food and Drug Administration (FDA), US regulatory submission, ViiV Healthcare, Ziba Shamsi
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?